Avanir Pharmaceuticals

Pharmaceutical firm reports loss of $0.09 per share

Published in Lab Business Week, January 30th, 2005

Avanir Pharmaceuticals (AVN) reported a net loss attributable to common shareholders for the fourth quarter of fiscal 2004 of $8.6 million, or $0.09 per share, compared to $7.0 million, or $0.11 per share for the same period in 2003.

Contributing to the current period loss are the company's expenditures related to ongoing clinical development programs and a $2.7 million non-cash charge for the issuance of common stock to the Ciblex Corporation in connection with the MIF technology.

The company's operating expenditures were partially offset by revenues from government research grants and license agreements.

Research and development...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-01-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry